A blockbuster diabetes drug called Invokana has pulled in hundreds of millions of dollars for Big Pharma, but the FDA recently announced that the treatment is causing even more problems in diabetics.
Invokana has been available in the U.S. since early 2013, and its sales have been huge- $278 million in the first quarter of 2015 alone. However, the FDA has recently linked Invokana to a serious condition called diabetic ketoacidosis, a condition which can lead to major organ failure and even death if not treated timely and appropriately. Moreover, early indications from a study suggests Invokana also presents a significant increased risk of heart attack and stroke.
Other serious adverse events were also identified, with five different adverse effects related directly or indirectly to renal toxicity, including kidney failure or impairment, dehydration, fluid imbalances, kidney stones, urinary tract infections, and abnormal weight loss.